

ONCOLYTICS BIOTECH INC

Form 6-K

March 03, 2006

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 6-K

Report of Foreign Private Issuer

**Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

For the month of **March 2006**

Commission File Number 000-31062

Oncolytics Biotech Inc.

(Translation of registrant's name into English)

**Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's home country), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 - _____

TABLE OF CONTENTS

Signatures

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc.
(Registrant)

Date **March 3, 2006**

By: /s/ Doug Ball

Doug Ball
Chief Financial Officer

Table of Contents

210, 1167 Kensington Cr. N.W
Calgary, Alberta
Canada T2N 1X7

FOR IMMEDIATE RELEASE

Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2005

CALGARY, AB, March 3, 2006 Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (Oncolytics or the Company) today reported its financial results for the year ended December 31, 2005.

We are encouraged by the results we are observing and the progress we have made in both our preclinical and clinical programs, said Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. In 2005, we expanded our clinical program into the U.S., commenced our first co-therapy study in the U.K. and presented positive interim results from our first systemic administration study.

Selected Highlights:

Strengthened the financial base by raising net proceeds of \$18.8 million to help fund the planned Phase II program;

Reported interim results from a Phase I systemic administration trial in the U.K that demonstrated REOLYSIN® was well tolerated and can be delivered to and show activity in a variety of tumour types and locations in the body;

Expanded the clinical program with the approval and commencement of enrolment for a Phase I combination REOLYSIN®/radiation trial in the U.K. and a Phase I systemic delivery trial in the U.S.;

Received clearance to commence a Phase I/II recurrent malignant glioma (brain cancer) study in the U.S., while concluding enrolment in a Phase I recurrent malignant glioma clinical trial in Canada;

Presented promising preclinical research at two AACR conferences in the areas of immune interaction and co-therapy with existing chemotherapies and radiation;

Appointed Dr. Karl Mettinger to the position of Chief Medical Officer;

Expanded the company's intellectual property portfolio with the issue of its first four Canadian patents and a second European patent in 2005, and a 14th U.S. patent in early 2006; and,

Announced in January 2006 that the U.S. National Cancer Institute is seeking proposals to conduct a Phase II systemic administration trial for patients with melanoma, and a Phase I/II systemic and intraperitoneal trial for patients with ovarian cancer.

Table of Contents**Oncolytics Biotech Inc.
BALANCE SHEETS**

As at December 31

| | 2005 | 2004 |
|--|-------------------|-------------------|
| | \$ | \$ |
| ASSETS | | |
| Current | | |
| Cash and cash equivalents | 3,511,357 | 12,408,516 |
| Short-term investments | 36,894,810 | 21,510,707 |
| Accounts receivable | 47,390 | 47,767 |
| Prepaid expenses | 540,368 | 250,365 |
| | 40,993,925 | 34,217,355 |
| Capital assets | 189,863 | 261,688 |
| Intellectual property | 5,110,538 | 4,997,598 |
| Investments | $\frac{3}{4}$ | 12,000 |
| | 46,294,326 | 39,488,641 |
| LIABILITIES AND SHAREHOLDERS EQUITY | | |
| Current | | |
| Accounts payable and accrued liabilities | 1,692,481 | 949,258 |
| Alberta Heritage Foundation loan | 150,000 | 150,000 |
| Commitments and contingency | | |
| Shareholders equity | | |
| Share capital | | |
| Authorized: unlimited | | |
| Issued: 36,236,748 (2004 31,915,496) | 84,341,212 | 66,643,325 |
| Warrants | 4,429,932 | 3,347,630 |
| Contributed surplus | 6,413,243 | 6,349,139 |
| Deficit | (50,732,542) | (37,950,711) |
| | 44,451,845 | 38,389,383 |
| | 46,294,326 | 39,488,641 |

Table of Contents

Oncolytics Biotech Inc.
STATEMENTS OF LOSS AND DEFICIT

For the periods ended December 31

| | 2005 | 2004 | 2003 | Cumulative from inception on April 2, 1998 to December 31, 2005 |
|---|-------------------|-------------|-------------|--|
| | \$ | \$ | \$ | \$ |
| Revenue | | | | |
| Rights revenue | ¾ | ¾ | ¾ | 310,000 |
| Interest income | 783,456 | 699,757 | 313,305 | 3,569,196 |
| | 783,456 | 699,757 | 313,305 | 3,879,196 |
| Expenses | | | | |
| Research and development | 9,308,977 | 7,107,998 | 2,818,962 | 32,835,505 |
| Operating | 3,084,897 | 2,803,669 | 2,449,478 | 13,090,691 |
| Stock based compensation | 64,104 | 2,668,570 | 996,707 | 3,762,099 |
| Foreign exchange loss | 253,608 | 358,068 | 2,881 | 613,578 |
| Amortization intellectual property | 786,459 | 686,717 | 594,353 | 3,162,791 |
| Amortization capital assets | 69,532 | 65,039 | 69,171 | 355,046 |
| | 13,567,577 | 13,690,061 | 6,931,552 | 53,819,710 |
| Loss before the following: | 12,784,121 | 12,990,304 | 6,618,247 | 49,940,514 |
| Gain on sale of BCY LifeSciences Inc. | (765) | (34,185) | (264,453) | (299,403) |
| Loss on sale of Transition Therapeutics Inc. | ¾ | ¾ | 2,156,685 | 2,156,685 |
| Loss before taxes | 12,783,356 | 12,956,119 | 8,510,479 | 51,797,796 |
| Capital tax (recovery) | (1,525) | ¾ | 33,552 | 49,746 |
| Future income tax recovery | ¾ | ¾ | ¾ | (1,115,000) |
| Net loss for the year | 12,781,831 | 12,956,119 | 8,544,031 | 50,732,542 |
| Deficit, beginning of year | 37,950,711 | 24,994,592 | 16,450,561 | ¾ |

| | | | | |
|---|-------------------|------------|------------|------------|
| Deficit, end of year | 50,732,542 | 37,950,711 | 24,994,592 | 50,732,542 |
| Basic and diluted loss per share | (0.39) | (0.45) | (0.35) | |

Table of Contents

Oncolytics Biotech Inc.
STATEMENTS OF CASH FLOWS

For the periods ended December 31

| | 2005 | 2004 | 2003 | Cumulative from inception on April 2, 1998 to December 31, 2005 |
|---|---------------------|--------------|--------------|--|
| | \$ | \$ | \$ | \$ |
| OPERATING ACTIVITIES | | | | |
| Net loss for the year | (12,781,831) | (12,956,119) | (8,544,031) | (50,732,542) |
| Deduct non-cash items | | | | |
| Amortization intellectual property | 786,459 | 686,717 | 594,353 | 3,162,791 |
| Amortization capital assets | 69,532 | 65,039 | 69,171 | 355,046 |
| Stock based compensation | 64,104 | 2,668,570 | 996,707 | 3,762,099 |
| Loss on sale of Transition Therapeutics Inc. | | | 2,156,685 | 2,156,685 |
| Other non-cash items | 224,508 | 379,895 | (261,572) | (773,148) |
| Net changes in non-cash working capital | 584,766 | (69,065) | (489,051) | 1,092,999 |
| Cash used in operating activities | (11,052,462) | (9,224,963) | (5,477,738) | (40,976,070) |
| INVESTING ACTIVITIES | | | | |
| Intellectual property | (1,033,035) | (958,809) | (1,045,869) | (4,656,670) |
| Capital assets | (61,309) | (15,230) | (50,729) | (587,511) |
| Purchase of short-term investments | (22,195,253) | (6,777,179) | (18,111,608) | (47,084,040) |
| Redemption of short-term investments | 6,656,746 | 3,114,000 | | 9,770,746 |
| Investment in BCY LifeSciences Inc. | 7,965 | 133,609 | 450,151 | 464,602 |
| Investment in Transition Therapeutics Inc. | | | 2,552,695 | 2,532,343 |
| Cash used in investing activities | (16,624,886) | (4,503,609) | (16,205,360) | (39,560,530) |
| FINANCING ACTIVITIES | | | | |
| Alberta Heritage Foundation loan | | ¾ | ¾ | 150,000 |
| Proceeds from exercise of stock options and warrants | 3,384,787 | 8,121,296 | 700,882 | 14,967,068 |
| Proceeds from private placements | 15,395,402 | 6,223,763 | 9,844,700 | 38,137,385 |
| Proceeds from public offerings | | 9,150,902 | 5,459,399 | 30,793,504 |
| Cash provided by financing activities | 18,780,189 | 23,495,961 | 16,004,981 | 84,047,957 |

| | | | | |
|---|---------------------------------|---------------|-------------|-----------|
| Increase (decrease) in cash and cash equivalents during the period | (8,897,159) | 9,767,389 | (5,678,117) | 3,511,357 |
| Cash and cash equivalents, beginning of the period | 12,408,516 | 2,641,127 | 8,319,244 | |
| Cash and cash equivalents, end of the period | 3,511,357 | 12,408,516 | 2,641,127 | 3,511,357 |
| Cash interest received | 993,097 | 459,757 | 187,843 | |
| Cash taxes paid (net) | $\frac{3}{4}$ | $\frac{3}{4}$ | 1,552 | |

Table of Contents

To view the Notes to the Company's Financial Statements and Management's Discussion and Analysis, please see the Company's 2005 Annual Filings which will be available on www.sedar.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone and in combination with radiation. For further information about Oncolytics please visit www.oncolyticsbiotech.com

This press release contains forward looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements, including the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2006 and beyond, the Company's planned expansion, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the ability of the technology to strengthen the core technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs and the Company's planned expansion of such programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward looking statements. The Company does not undertake to update these forward looking statements.

FOR FURTHER INFORMATION PLEASE CONTACT:

Oncolytics Biotech Inc.
Cathy Ward
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
Tel: 403.670.7377
Fax: 403.283.0858
cathy.ward@oncolytics.ca
www.oncolyticsbiotech.com

The Equicom Group
Nick Hurst
20 Toronto Street
Toronto, Ontario M5C 2B8
Tel: 416.815.0700 ext.226
Fax: 416.815.0080
nhurst@equicomgroup.com

The Investor Relations Group
Damian McIntosh
11 Stone St, 3rd Floor
New York, NY 10004
Tel: 212.825.3210
Fax: 212.825.3229
dmcintosh@investorrelationsgroup.com

RenMark Financial Communications
John Boidman
2080 Rene Levesque Blvd. W.
Montreal, PQ H3H 1R6
Tel: 514.939.3989
Fax: 514.939.3717
jboidman@renmarkfinancial.com

-30-